Celgene's $5.5M Patent Buy Ends Cancer-Therapy IP Row
Biopharmaceutical company Cyclacel Pharmaceuticals Inc. has agreed to sell four patents to rival Celgene Corp. for $5.5 million, ending federal litigation in Delaware over the validity of the patents and whether...To view the full article, register now.
Already a subscriber? Click here to view full article